Abstract
This report synthesizes the outcomes of an interdisciplinary conference held in Munich in 2025 to evaluate the impact of the EU Veterinary Medicinal Products Regulation (EU) 2019/6 (1) and associated legislation on innovation in the animal health sector. It highlights the regulatory, scientific, and commercial challenges faced by stakeholders and proposes strategic actions to foster innovation, particularly in the context of limited markets, novel therapies, and sustainability. The report draws on expert presentations and panel discussions, offering a comprehensive overview of the current landscape and a call for regulatory and procedural adaptations to support the development and availability of veterinary medicinal products (VMPs).